Recently, pharmaceutical companies have been pricing many of their products at astounding values. A couple years ago, in fact, an amazing new hepatitis C drug came to market priced at about $90,000 per patient. But since that time, several other companies have come to market with competing products. That has brought the overall price of these drugs down, and we are finally seeing a decline in how much money we are spending treating hepatitis C. Here is a picture of that decline, which he came across thanks to @Altarum_CSHS:
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.